Trial · NCT06245629
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
NCT06245629, Recruiting, Uppsala University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma. Trials, record NCT06245629. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06245629
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
- NCT number
- NCT06245629
- Status
- Recruiting
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Uppsala University
- Conditions
- Myeloma Multiple
- Interventions
- Bortezomib-bendamustine-melphalan
- First posted
- 2024-02-07
- Last updated
- 2024-11-29
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean difference in time to next treatment (TNT) after ASCT1 and ASCT2 for each individual patient | 0.2-18 years | Average time to next myeloma treatment within each individual patient making each patient as its' own control |
| Secondary | Median time to next treatment after ASCT2 | 0-18 years | Time to start of next myeloma treatment after ASCT2 |
| Secondary | Median progression free survival (PFS) after ASCT2 | 0-18 years | Time to progression or death after ASCT2 |
| Secondary | Median overall survival after ASCT2 | 0-18 years | Survival until death from any cause |
| Secondary | Depth of best response after ASCT2 | 0-24 months | Best result after given treatment for myeloma |
| Secondary | Treatment related mortality | 0-12 months | Death due to any transplantation-related cause other than disease progression. |
| Secondary | Mean duration of neutropenia at ASCT2 | 7-50 days | Absolute neutrophil count (ANC) \<0.5 x10\^9 |
| Secondary | Mean time until engraftment at ASCT2 | 5-50 days | Days from ASCT until ANC of 0.5 x 109/L or higher and total platelet count of 20 x 109/L and rising, without transfusion of thrombocytes. |
| Secondary | Mean duration of hospitalization at ASCT2 | 7-50 days | Days from ASCT until discharge |
| Secondary | Frequency of severe adverse events at ASCT2 | 100 days | All serious adverse events according to version 5.0 of National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) during hospitalization and until day +100 after ASCT2. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06245629
GET https://conductscience.org/api/trials/v1/NCT06245629/registered